PT  - JOURNAL ARTICLE
AU  - ALAN D. SMITH
AU  - MATHEW TRUONG
AU  - ROB BRISTOW
AU  - PAUL YIP
AU  - MICHAEL F. MILOSEVIC
AU  - ANTHONY M. JOSHUA
TI  - The Utility of Serum CA9 for Prognostication in Prostate Cancer
DP  - 2016 Sep 01
TA  - Anticancer Research
PG  - 4489--4492
VI  - 36
IP  - 9
4099  - http://ar.iiarjournals.org/content/36/9/4489.short
4100  - http://ar.iiarjournals.org/content/36/9/4489.full
SO  - Anticancer Res2016 Sep 01; 36
AB  - Background/Aim: Carbonic anhydrase IX (CA9) catalyses the interconversion of carbon dioxide to carbonic acid and bicarbonate and is considered a putative biomarker of tumour hypoxia. We set out to evaluate the prognostic significance of CA9 in prostate cancer. Patients and Methods: Plasma samples were assessed from 68 men with high-risk localised prostate cancer treated with radical prostatectomy (RP) or radiotherapy (RT), and 20 men with castration-resistant prostate cancer (CRPC) treated with docetaxel chemotherapy between 2010 and 2012 at the Princess Margaret Cancer Centre, Canada. Results: Of the 68 patients with high-risk localised prostate cancer, 57 underwent RP and 11 underwent RT. Baseline CA9 was not associated with recurrence or prostate-specific antigen in either group (p=0.98 and 0.20, respectively). CA9 levels before chemotherapy correlated with overall survival (r=−0.37; two-sided p=0.11). Conclusion: Baseline CA9 in men with CRPC may portend a more aggressive prostate cancer phenotype with poorer survival.